Orthobiologic product maker Bioventus has invested $2.5m in Israel-based orthobiologic implant developer CartiHeal, increasing its latest financing round to $21m.

The round was led by life sciences-focused venture capital fund aMoon and included Johnson & Johnson Innovation – JJDC, the corporate venturing arm of pharmaceutical group Johnson & Johnson, as well as investment holding company Elron and VC fund Peregrine Ventures.

CartiHeal is developing a porous, biocompatible calcium carbonate bio-scaffold called Agili-C that will be used to treat cartilage and…